DIRAS3 and non-small cell lung carcinoma: Accordingly, we explored whether DIRAS3 affected the expression of the RAS/ERK pathway in NSCLC, and the results of the Western blot assay illustrated that knockdown of DIRAS3 in HCC827 cells increased RAS and p-ERK/ERK expression levels (Figure 5(a)), while over-expression of DIRAS3 in A549 cells decreased RAS and p-ERK/ERK expression levels (Figure 5(b)).